FDA will consider expanded use of Astellas' cancer drug erlotinib

01/18/2013 | Pharmaceutical Business Review Online

Astellas Pharma said the FDA has accepted its supplemental new drug application for Tarceva, or erlotinib, as a first-line treatment for EGFR-positive metastatic or locally advanced nonsmall-cell lung cancer. The application was given priority-review designation.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR